Incidence, severity and factors related to drug-induced keratoepitheliopathy with glaucoma medications.
OBJECTIVE
To evaluate the incidence, severity, and factors related to drug-induced keratoepitheliopathy in eyes using antiglaucoma eye drops.


METHODS
In a cross-sectional study, 749 eyes from 427 patients who had used one or more antiglaucoma eye drops were examined at Niigata University Medical and Dental Hospital or related facilities. The incidence and severity of superficial punctate keratitis (SPK), patient gender and age, type of glaucoma, and type of eye drops were recorded. SPK was graded according to the AD (A, area; D, density) classification. The severity score (SS) was calculated from A x D.


RESULTS
SPK was observed in 382 (51.0%) of 749 eyes that had received any type of antiglaucoma eye drops. While 254 eyes (33.9%) were classified as A1D1 (SS 1), 34 eyes (4.6%) had severe SPK with SS 4 or more. The number of eye drops and the total dosing frequency per day were significantly greater in SPK-positive eyes than in eyes without SPK. The number of eye drops was proportional to the frequency and severity of SPK. Among eyes that were treated with three or more eye drops, SPK was more severe and more frequent in older patients (>/=71 years). In addition, a considerable difference was detected for each type of glaucoma.


CONCLUSIONS
Drug-induced keratoepitheliopathy is often observed in eyes that have received recent antiglaucoma eye drops. The number of eye drops, the total dose frequency per day, patient age, and type of glaucoma may affect this condition. We have to consider not only the effects on intraocular pressure but also the incidence and severity of drug-induced keratoepitheliopathy as a frequent side effect of glaucoma medications.
Fukuchi
Takeo
T
Division of Ophthalmology and Visual Science, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan.
Wakai
Kimiko
K
Suda
Kieko
K
Nakatsue
Tomoko
T
Sawada
Hideko
H
Hara
Hiroaki
H
Ueda
Jun
J
Tanaka
Takayuki
T
Yamada
Akiko
A
Abe
Haruki
H
Am J Ophthalmol. 1979 Oct;88(4):739-43
507147
Ophthalmic Res. 2000 Jan-Feb;32(1):3-8
10657748
Ophthalmology. 2006 Aug;113(8):1333-9
16877072
Arch Ophthalmol. 1998 Aug;116(8):1003-10
9715679
Ophthalmology. 1992 Jul;99(7):1082-8
1495787
Am J Ophthalmol. 1998 Sep;126(3):400-8
9744373
Surv Ophthalmol. 1980 Jul-Aug;25(1):15-30
6998034
J Glaucoma. 2003 Dec;12(6):486-90
14646684
J Glaucoma. 2008 Aug;17(5):350-5
18703943
Curr Eye Res. 2000 Feb;20(2):85-94
10617908
J Glaucoma. 2007 Jan;16(1):98-103
17224758
Ophthalmology. 1980 May;87(5):451-4
7402591
Ophthalmology. 1996 Jan;103(1):138-47
8628544
Br J Ophthalmol. 1994 May;78(5):377-80
7912954
Br J Ophthalmol. 1998 Jan;82(1):39-42
9536878
Invest Ophthalmol. 1976 Apr;15(4):246-59
1262158
Nippon Ganka Gakkai Zasshi. 2009 May;113(5):576-82
19489448
Arch Ophthalmol. 2003 Nov;121(11):1537-9
14609908
J Ocul Pharmacol Ther. 2003 Dec;19(6):517-25
14733709
Acta Ophthalmol Scand. 1999 Oct;77(5):541-3
10551296
Invest Ophthalmol Vis Sci. 1999 Mar;40(3):619-30
10067965
J Glaucoma. 2003 Dec;12(6):480-5
14646683
Cornea. 2006 Dec;25(10):1133-8
17172885
Ophthalmology. 1995 Dec;102(12):1743-52
9098273
Br J Ophthalmol. 1993 Sep;77(9):590-6
8218059
Ophthalmology. 1996 Jan;103(1):126-37
8628543
J Glaucoma. 2008 Apr-May;17(3):217-22
18414108
Br J Ophthalmol. 2002 Apr;86(4):418-23
11914211
Br J Ophthalmol. 1990 Jul;74(7):409-12
2378856
Invest Ophthalmol Vis Sci. 2005 Jul;46(7):2444-50
15980234
J Glaucoma. 1996 Feb;5(1):68-74
8795737